• Publications
  • Influence
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological features of disrupted neuronal excitability and plasticity within limbic structures of the brain. TheseExpand
  • 953
  • 38
  • PDF
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol
In a randomized, double-blind trial, patients with acute bipolar mania received 1-6 mg/day of risperidone, 2-12 mg/day of haloperidol, or placebo for 3 weeks, followed by double-blind risperidone orExpand
  • 160
  • 17
Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Nat. Med. 13, 1102–1107 (2007); published online 2 September 2007; corrected after print 17 September 2007 In the version of this article initially published, the name of one person acknowledged wasExpand
  • 46
  • 2
Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a
OBJECTIVE Noninterventional, naturalistic studies facilitate examination of current clinical practices and provide an understanding of the impact of the biopsychosocial aspects of schizophrenia. ThisExpand
  • 23
  • 2
Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes.
  • M. Tohen, C. Bowden, +8 authors W. Greil
  • Psychology, Medicine
  • The British journal of psychiatry : the journal…
  • 1 February 2008
BACKGROUND Combinations of olanzapine and carbamazepine are often used in clinical practice in the management of mania. AIMS To assess the efficacy and safety of olanzapine plus carbamazepine inExpand
  • 72
  • 1
  • PDF
[Personality disorders and depression].
Comorbid relations between personality disorders (PD) of affective and non-affective types (anxiety-hypochondriac character) and depression were analyzed in 35 patients including 13 men (37.1%) andExpand
  • 29
  • 1
Sluggish schizophrenia in the modern classification of mental illness.
The concept of latent schizophrenia was developed by E. Bleuler (1911) and was further promoted in the studies of a number of research psychiatric schools of Europe, the United States, Japan, andExpand
  • 21
  • 1
  • PDF
[Psychodermatology: current state of the problem].
An analysis of comorbidity of psychiatric and dermatological pathology in historical, epidemiological and clinical aspects is presented. Psychocutaneous disorders (delusional parasitosis,Expand
  • 5
  • 1
[The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].
Glutamate neurotransmission has been considered as one of pathogenetic factors of schizophrenia though all antipsychotics widely used in modern psychiatric practice are dopamine antagonists.Expand
  • 2
  • 1
The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity
Examination of patients with various forms of anxiety and phobic disorders (according to DSM-4 criteria) demonstrated a considerable shortening of enkephalin half-life and reduced total enkephalinaseExpand
  • 12
  • PDF